Hua Medicine Ltd., an innovative, clinical-stage biotechnology company in Shanghai, announced the closing of a $25 million Series B financing.
Hua Medicine Ltd., a leading innovative drug development company in China, announced today the start of multicenter, multi-dose Phase 1b Trials for Diabetes. The company had previously announced positive results from a Phase 1a trial evaluating HMS5552, a glucokinase activator (GKA) for Type 2 Diabetes, and demonstrated, even at single doses, significant effects in a variety of biochemical diabetes markers such as glucose and glucose-stimulated insulin release (GSIR).
Hua Medicine, the leading innovative drug development and commercialization company in China, and Roche announced today a licensing agreement for Roche's Glucokinase Activator (GKA) program.
Hua Medicine, the leading innovative drug development and commercialization company in China, announced today that it has secured $50 million in new financing commitments from a prestigious group of US and Chinese healthcare investors, including ARCH Venture Partners, Fidelity Biosciences, Fidelity Growth Partners Asia, Venrock, Sino-Alliance International Ltd and new investor WuXi PharmaTech Corporate Venture.
Dear Hua Medicine Board Directors, Advisors, Colleagues, Partners and Friends